Final Overall Survival of the Phase III Randomised Trial of Chemotherapy with and without Bevacizumab for Advanced Cervical Cancer: An NRG Oncology/Gynecologic Oncology Group Study

BACKGROUND: On August 14, 2014, the United States Food and Drug Administration approved the anti-angiogenesis drug, bevacizumab, for women with advanced cervical cancer based on a 2012 interim analysis of 271 deaths on GOG protocol 240. We now report the planned protocol-specified final analysis of...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Lancet
Autori principali: Tewari, Krishnansu S., Sill, Michael W., Penson, Richard T., Huang, Helen, Ramondetta, Lois M., Landrum, Lisa M., Oaknin, Ana, Reid, Thomas J., Leitao, Mario M., Michael, Helen E., DiSaia, Philip J., Copeland, Larry J., Creasman, William T., Stehman, Frederick B., Brady, Mark F., Burger, Robert A., Thigpen, J. Tate, Birrer, Michael J., Waggoner, Steven E., Moore, David H., Look, Katherine Y., Koh, Wui-Jin, Monk, Bradley J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2017
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5714293/
https://ncbi.nlm.nih.gov/pubmed/28756902
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(17)31607-0
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi